The DOI matches its Crossref record.
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Abstract
UNLABELLED: Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical trials have validated the clinical importance of anti-VEGF or anti-VEGF receptor (VEGFR) therapy. Currently the humanized monoclonal antibody bevacizumab (blocks VEGF-A), and the tyrosine kinase inhibitors sunitinib and sorafenib (inhibit VEGFRs) are approved for patients with various malignancies and several others are expected in the coming years. Unfortunately, anti-VEGF/VEGFR treatment is not void of side effects. An array of unexpected side effects is now seen in clinical practice. Management of these side effects is extremely important in the development of the various anti-VEGF/VEGFR therapies and their optimal use. This review provides an overview of the toxicity profile of this class of agents, the molecular basis behind these side effects and indicates potential options for management. VEGF and its receptors play an important role in normal tissues and are widely expressed. It is likely that interference with this pathway induces an array of side effects due to the lack of normal function of VEGF. A consistent pattern of side effects is now emerging. Hypertension, gastro-intestinal toxicity, hypothyroidism, proteinuria, coagulation disorders and neurotoxicity are side effects observed with both anti-VEGF and anti-VEGFR inhibitors. For these side effects the role of VEGF/VEGFR pathway in normal tissue was reviewed in order to provide a molecular mechanism that linked side effect with physiological activity of VEGF/VEGFR. Insight into the molecular basis may aid specific supportive care measures to ensure optimal use of this class of agents. CONCLUSION: Inhibiting the VEGF/VEGFR pathway is an effective approach to treat cancer. It has also provided new insight into the physiological role of this pathway in various organs. Integrating the knowledge in daily oncological practice will be a challenge for the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
McTigue, M., Murray, B. W., Chen, J. H., Deng, Y.-L., Solowiej, J., & Kania, R. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207759109 · Cited by 592
Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 579
Molecular Mediators of Angiogenesis
Ucuzian, A. A., Gassman, A. A., East, A. T., & Greisler, H. P. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181c7ed82 · Cited by 446
Altmann, C., & Schmidt, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010110 · Cited by 402
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0538-7 · Cited by 270
Metadata
- Authors
- Roodhart, J., Langenberg, M., Witteveen, E., & Voest, E.
- Venue
- Current Clinical Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-05-01
- Volume
- 3
- Issue
- 2
- Pages
- 132-143
- ISSN
- 1574-8847 (ISSN-L)
- OpenAlex
- W2105121109
- Cited by
- 204
- References
- 0
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. https://app.cochat.ai/papers/10.2174/157488408784293705
- The paper
- Roodhart, J., Langenberg, M., Witteveen, E., & Voest, E. (2008). The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. Current Clinical Pharmacology. https://doi.org/10.2174/157488408784293705
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.